Anavex Life Sciences Corp (AVXL)

[raja48185]

FWIW from the Yahoo MB (SAVA Conversation).

Asked by STAT to examine the simufilam data, Alzheimer’ scientists not involved in Cassava’s study said the cognitive benefit claim was exaggerated and not supported by the design of the clinical trial.

The conclusions reached by Cassava about simufilam’s benefit for Alzheimer’s patients are “overblown, inappropriate, and naive,” said Rob Howard, an Alzheimer’s researcher and professor of psychiatry at University College London. “It’s the sort of presentation that one might expect an undergraduate to make.”

Lon Schneider, a physician and Alzheimer’s expert at the Keck School of Medicine of the University of Southern California, described Cassava’s study results as “uninterpretable.”